Work

MO01.18 An indirect Comparison of Pembrolizumab+Chemo vs Ipilimumab+Nivolumab as First-Line Therapies in Patients with PD-L1 TPS≥1% Metastatic NSCLC

Year: 2021

Type: conference-abstract

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2020.10.066

Authors: B. Halmos, T. Burke, C. Kalyvas, R. Insinga, K. Vandormael, A. Frederickson, B. Piperdi

Institutions: Albert Einstein College of Medicine, Montefiore Einstein Comprehensive Cancer Center, Merck & Co., Inc., Rahway, NJ, USA (United States), MSD (Belgium), MSD (Belgium)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3120622126

Cites:

Cited by:

Related to: 10